X

Trial Profile

Trastuzumab in a Neo-Adjuvant Regimen for HER2+ Breast Cancer - the TRAIN 2 Study

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Mar 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab (Primary) ; Carboplatin; Cyclophosphamide; Epirubicin; Fluorouracil; Paclitaxel; Trastuzumab
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms TRAIN-2

Most Recent Events

21 Mar 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2030.
13 Sep 2022 Results of A TRAIN-2 sub study presented at the 47th European Society for Medical Oncology Congress
21 Mar 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com